PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21778904-6 2011 Extracorporeal photochemotherapy has been shown to be effective in the treatment of CTCL consisting of reinfusion of 3 to 9 x 10 leukocytes, taken from the patient by leukopheresis and treated in an extracorporeal system with 8-methoxypsoralen and UVA. Methoxsalen 226-243 TSPY like 2 Homo sapiens 84-88 12126205-1 2002 Photopheresis, a leukapheresis-based therapy that combines 8-methoxypsoralen (8-MOP) and ultraviolet-A irradiation, has been shown to be an effective treatment for advanced cutaneous T cell lymphoma (CTCL), but also appears to be effective in certain patients with systemic sclerosis (SSc) and chronic graft versus host disease (cGVHD). Methoxsalen 59-76 TSPY like 2 Homo sapiens 200-204 2585773-3 1989 CTCL patients were treated by photochemotherapy with topical 8-methoxypsoralen (8-MOP) followed by VUA irradiation, electron-beam irradiation, or systemic chemotherapy. Methoxsalen 61-78 TSPY like 2 Homo sapiens 0-4 8534123-1 1995 Extracorporeal photopheresis (ECP) using UVA irradiation of enriched lymphocytes in the presence of 8-methoxypsoralen as a photoactivatable substrate was originally introduced as a therapeutic regimen for cutaneous T-cell lymphoma (CTCL). Methoxsalen 100-117 TSPY like 2 Homo sapiens 232-236 10155561-2 1994 Several independent and multicenter trials using lymphapheresis with 8-methoxypsoralen (8-MOP) activated by shortwave ultraviolet light have demonstrated the clinical benefit of this modality for treatment of advanced CTCL. Methoxsalen 69-86 TSPY like 2 Homo sapiens 218-222 10155561-2 1994 Several independent and multicenter trials using lymphapheresis with 8-methoxypsoralen (8-MOP) activated by shortwave ultraviolet light have demonstrated the clinical benefit of this modality for treatment of advanced CTCL. Methoxsalen 88-93 TSPY like 2 Homo sapiens 218-222 10651689-4 2000 In CTCL there is an accumulating body of evidence to show that 8-methoxypsoralen-treated cells display increased quantities of antigenic peptides at their cell surfaces, and this in turn leads to an enhanced cytotoxic response against the neoplastic T-cell population. Methoxsalen 63-80 TSPY like 2 Homo sapiens 3-7 1914077-1 1991 Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen (8-MOP) and ultraviolet light, a procedure known as PUVA, has been found to be useful in the management of systemically disseminated cutaneous T-cell lymphoma (CTCL). Methoxsalen 53-70 TSPY like 2 Homo sapiens 231-235 1914077-1 1991 Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen (8-MOP) and ultraviolet light, a procedure known as PUVA, has been found to be useful in the management of systemically disseminated cutaneous T-cell lymphoma (CTCL). Methoxsalen 72-77 TSPY like 2 Homo sapiens 231-235 2585773-3 1989 CTCL patients were treated by photochemotherapy with topical 8-methoxypsoralen (8-MOP) followed by VUA irradiation, electron-beam irradiation, or systemic chemotherapy. Methoxsalen 80-85 TSPY like 2 Homo sapiens 0-4 6609177-2 1984 In 1975 we started a prospective study on oral methoxsalen photochemotherapy (PUVA) in cutaneous T cell lymphoma (CTCL). Methoxsalen 47-58 TSPY like 2 Homo sapiens 114-118 3058601-1 1988 8-Methoxypsoralen (8-MOP) is a photoactivated drug used clinically in the treatment of psoriasis and cutaneous T-cell lymphoma (CTCL). Methoxsalen 0-17 TSPY like 2 Homo sapiens 128-132 3058601-1 1988 8-Methoxypsoralen (8-MOP) is a photoactivated drug used clinically in the treatment of psoriasis and cutaneous T-cell lymphoma (CTCL). Methoxsalen 19-24 TSPY like 2 Homo sapiens 128-132